Ultrasonography capable of detecting endometrial cancer before symptoms are evident in postmenopausal women

December 12, 2010

Transvaginal ultrasound screening (TVS) has good (80󈟆%) sensitivity and specificity at detecting endometrial cancer before symptoms appear in postmenopausal women, according to the first large-scale study to assess the performance of TVS screening for endometrial cancer. However, the findings published Online First in The Lancet Oncology, report that further studies to examine acceptability, health economics, and risk are needed before routine population screening or targeted screening for endometrial cancer can be advocated.

Endometrial cancer is the most common gynaecological cancer. But because of the good prognosis of patients with endometrial cancer compared with other cancers, few studies have been done to assess the benefits of screening in asymptomatic women (without bleeding). However, increasing obesity, falling fertility, and an aging population suggest that incidence will continue to rise.

To date, no screening test to detect early stage endometrial cancer in asymptomatic women has been shown to be effective. Measuring endometrial thickness with TVS (a technique commonly used to assess symptomatic women with abnormal vaginal bleeding) has been suggested as a possible screening method.

To investigate the performance of TVS screening on a large scale, a team led by Ian Jacobs from University College, London, UK, analysed data from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). As part of the trial, TVS was performed on 37 038 postmenopausal women.

The researchers calculated the performance characteristics of endometrial thickness (ET) and endometrial abnormalities at detecting endometrial cancer within 1 year of TVS screening, and examined the sensitivity and specificity of TVS for different risk groups. Modelling using epidemiological variables was done to assess a screening strategy for women at higher risk.

In the 133 women diagnosed with endometrial cancer or atypical endometrial hyperplasia (AEH) within 1 year of screening, 107 (81%) had an ET of 5mm or greater. Most of the 36 731 women who did not have cancer had an ET of less than 5mm.

At the optimum ET cutoff of 5.15mm, TVS would detect 80.5% of cancer cases (sensitivity) and would have a 14.3% false-positive rate (85.7% specificity). Using this threshold, if the entire population were screened, one case of endometrial cancer would be detected for every 47.7 women.

The authors point out that although the number of false positives could be reduced substantially by increasing the cutoff for ET, this would result in a corresponding fall in sensitivity. An increased cutoff of 10mm would detect 54.1% of cancer cases with 97.2% specificity, and 17 women would undergo further procedures to detect each case of endometrial cancer.

When the analysis was restricted to the 96 women with cancer who reported no symptoms of postmenopausal bleeding at the scan, an ET cutoff of 5mm was able to detect 77.1% of women who developed cancer with a 14.2% false-positive rate.

Additionally, the modelling analysis identified 25% of the population as at high risk, and this high risk group included 40% of endometrial cancer or AEH cases. In this group, the optimum ET cutoff of 6.75mm would detect 84.3% of cancer cases and achieve a specificity of 89.9%. According to the researchers, "this would reduce the burden of screening to 25% of the population with detection of about 40% of the cases."

The authors say: "A targeted screening approach might help reduce the overall number of false-positive findings while maintaining a high sensitivity."

They conclude: "Although the role of population screening for endometrial cancer remains uncertain, the findings are of immediate value in the management of increased endometrial thickness in postmenopausal women undergoing pelvic scans for reasons other than vaginal bleeding...Our findings provide the basis for further studies to assess the acceptability, health economics, and risk stratification."

In a Comment, Ignace Vergote and colleagues from University Hospitals Leuven, Leuven, Belgium caution that the findings do not prove "a benefit for screening for endometrial cancer because of an absence of survival data."

They add: "The study...provides important ultrasonographic endometrial findings in asymptomatic postmenopausal women, but screening for endometrial cancer with ultrasonography has not been sufficiently proven to be beneficial because of the high cost, the prevalence of cancers that are not clinically relevant or hyperplasia, the number of unnecessary surgical interventions and associated morbidity, the presence of clinically detected symptoms such as bleeding that happen at an early stage in many women with endometrial cancer, and the absence of prospective randomised trial data that show a survival benefit in screened patients."
Professor Ian Jacobs, Dean Faculty of Biomedical Sciences and Head of Department of Gynaecological Oncology, University College, London, UK.
T) +44 (0)7734592233 E) i.jacobs@ucl.ac.uk

Professor Ignace Vergote, University Hospitals Leuven, Leuven, Belgium.
T) +32 (1)634 4208 or +32 (1)634 4635 E) ignace.vergote@uzleuven.be

For full Article and Comment see: http://press.thelancet.com/tloultra.pdf



Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.